Given the increasing utilization of selective RET inhibitors in lung cancer patients, these findings call for awareness and guidance of toxicity before initiating treatment with these drugs, as well as monitoring and timely management of AEs during long-term use. This evidence concerns the gene RET and lung carcinoma.